A US federal jury on Friday handed Merck & Co a major victory, clearing the drug maker of any responsibility in the death of a 53-year-old Florida man who had a heart attack after taking its once popular painkiller Vioxx for less than a month.
The verdict was the second court victory for Merck, and the first in a federal court. The company had argued in this case that plaintiff lawyers never proved any link between Vioxx and the heart attack Richard Irvin suffered in 2001. Merck's lawyers contended Irvin's age, gender and diet all put him at risk for heart attacks
It was also the second time jurors heard the case brought by Irvin's family. In Houston, where the case was heard in November and December because of damage from Hurricane Katrina, jurors were unable to reach a verdict. Merck won a state case in New Jersey last year while it lost one in Texas.
Irvin's widow, Evelyn Irvin Plunkett; the youngest of their three daughters, Ashley Irvin; and their only son, Richard Irvin III, all testified that Irvin's health had been excellent up to his heart attack.
Plunkett left the courtroom in tears without talking to reporters.
"Obviously the family is very upset," said her attorney, Andy Birchfield.
He said the biggest problem was Judge Eldon Fallon's ruling, shortly before the trial, that two of their experts -- a cardiologist and a pathologist -- could not testify that Vioxx was to blame for Irvin's heart attack. They were experts in their fields, but not about Vioxx, the judge ruled.
"With all due respect, we think that [ruling] was [in] error," Birchfield said. He said he would be talking with Plunkett about whether to appeal.
Phil Beck, a lawyer for Merck, said he believes the verdict indicates the jury found "that the Merck scientists lived up to their legal and ethical responsibilities when manufacturing and marketing Vioxx and making the decision to take Vioxx off the market."
Shares of Merck rose US$0.90, or 2.5 percent, in after-hours trading. They closed up US$0.07 at US$36.05 on Thursday in regular trading on the New York Stock Exchange.
The jury deliberated for 3 hours and 40 minutes, the shortest period of any of the four juries yet in Vioxx-related cases.
Observers said the verdict was a clear victory for Merck but that the company will face more formidable cases later on this year when it faces plaintiffs who took Vioxx for 18 months or longer. Merck removed Vioxx from the market after a study showed it doubled patients' risk of heart attacks and strokes after 18 months.
Still, Howard Erichson, a professor at Seton Hall Law School said this verdict may keep plaintiff lawyers from filing short-term use cases. It may also help Merck because the judge overseeing all the federal cases has said he wants to discuss a settlement after trying the first four.
"To the extent that ultimately there is a wide settlement, this win plays in Merck's favor," Erichson said.
But on the conference call, Merck senior vice president and general counsel Kenneth Frazier, reiterated that the company intends to try each case individually. So far, about 9,600 have been filed.
Frazier also said that the study which caused Merck to withdraw Vioxx may give plaintiff lawyers a data point to use in their cases, but they still face the burden of proof in proving that the drug was a cause of the heart attack or stroke. He said heart attacks are common and have many causes, including high blood pressure.
Irvin took Vioxx for back pain, but never saw a doctor about it. Instead, the resident of St. Augustine, Florida, called his son-in-law, an emergency-room physician who lived in another city. He hadn't been able to keep down the first two painkillers prescribed by Dr Richard Schirmer. After he tried a sample given to him by an acquaintance, he asked Schirmer for Vioxx.
Schirmer testified that if the label had included a warning about heart attack risk, he wouldn't have prescribed Vioxx for his father-in-law.
Much of the evidence put on by Plunkett's attorneys focused on whether Merck should have added a warning to the label after it learned in early 2000 that patients taking Vioxx in a drug test called VIGOR had five times as many heart attacks as those on naproxen, another painkiller.
In his closing argument, Birchfield noted epidemiologist Wayne Ray's testimony that the drug probably was to blame for 54 percent of all heart attacks among people who suffered them while taking Vioxx. In Irvin's case, he said, that meant a 54 percent chance that the drug was among reasons for the heart attack.
Merck learned of the VIGOR study results in 2000. Had it stopped selling Vioxx or put a warning label on the drug then, he said, Irvin's son-in-law, an emergency room physician, would not have prescribed Vioxx for Irvin in April 2001.
"Did they rein in their massive marketing campaign? ... No. They pushed on wide open," he said. And he quoted the comment of Dr Eric Topol, a cardiologist subpoenaed for videotaped testimony while at the Cleveland Clinic.
"He said that was human experimentation," Birchfield continued. "Merck was playing Russian roulette for money with Dickie Irvin."
Merck attorney Phil Beck countered that no physician testified that Vioxx caused Irvin's death.
"In fact, no doctor testified that Vioxx was even a small factor in Mr Irvin's heart attack and death," he said.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”